Brain Neurotherapy Bio, Inc (BNB) has merged with Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned, independently operated subsidiary of Bayer AG.
As members of the AskBio team, we will continue to research and develop gene therapies for patients living with neurodegenerative diseases, including ongoing clinical stage glial cell line-derived neurotrophic factor (GDNF) gene therapy programs for Parkinson’s disease and multiple system atrophy (MSA).
Along with our other AskBio colleagues, we will continue to work to create safer, more effective adeno-associated virus (AAV) gene therapies, accelerate their development and increase access to these for all those in need around the world. We look forward to embracing the AskBio mission, which is to lead innovative science and drive clinical outcomes to transform people’s lives.
Brain Neurotherapy Bio, Inc (BNB) has merged with Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned, independently operated subsidiary of Bayer AG.
As members of the AskBio team, we will continue to research and develop gene therapies for patients living with neurodegenerative diseases, including ongoing clinical stage glial cell line-derived neurotrophic factor (GDNF) gene therapy programs for Parkinson’s disease and multiple system atrophy (MSA).
Along with our other AskBio colleagues, we will continue to work to create safer, more effective adeno-associated virus (AAV) gene therapies, accelerate their development and increase access to these for all those in need around the world. We look forward to embracing the AskBio mission, which is to lead innovative science and drive clinical outcomes to transform people’s lives.
